
15+ launches supported
$2B+ potential commercial value unlocked
12 months from strategy to launch readiness value unlocked

Illuminations Strategy Group brings senior executive leadership built on 30 years across pharma, biotech, medical devices, and diagnostics — combining a rare attribute most advisors don’t deliver: strategic architect and operational executor.
From seed financing through commercial launch, from in-licensing negotiations to board-level investor communications, ISG delivers the high-touch advisory life sciences leaders need at their most consequential moments.
We’ve built commercial organizations from inception, led 15+ product launches generating $2B+ in cumulative revenue, and guided companies through the full spectrum of growth inflection points by connecting corporate vision to investor confidence to market execution.
See how strategic guidance has helped life sciences companies navigate complexity, unlock growth, and prepare for critical milestones — from seed-stage capital raises to first-in-class product launches and global commercial expansion.
.png)

15+ launches supported
$2B+ potential commercial value unlocked
12 months from strategy to launch readiness value unlocked

15+ launches supported
$2B+ potential commercial value unlocked
12 months from strategy to launch readiness value unlocked

15+ launches supported
$2B+ potential commercial value unlocked
12 months from strategy to launch readiness value unlocked

15+ launches supported
$2B+ potential commercial value unlocked
12 months from strategy to launch readiness value unlocked
High-touch strategic guidance to help life sciences innovators and executives navigate market complexities, align stakeholders, and make confident decisions across the product and company lifecycle.
Embedded executive leadership — Fractional CCO, CBO, or CMO — for life sciences companies that need senior commercial firepower without a full-time hire. Engagements include leading a $10M capital raise for a medical device innovator; structuring specialty therapy in-licensing deals for a rare disease company; and commercialization strategy and execution.
Defined-scope engagements for specific inflection points — capital raises, launch planning, in-licensing diligence, partner identification, market access strategy, and commercial organization design. Structured as a primary scope with additional workstreams available as needs evolve.
Seed through Series C support, convertible note bridges, board and investor communications, and capital structure narratives that align commercial strategy with funding milestones.
Strategic guidance through the moments that define enterprise value — first launch, partnership negotiations, market expansion, organizational scale-up, and capital events. Anticipate challenges, evaluate options, and position for sustainable growth.
We work with founders, executives, and investors across pharma, biotech, medical devices, and diagnostics — bringing seasoned commercial leadership to the strategic decisions that define enterprise value.
We work with innovators, investors, and executives across the life sciences ecosystem to bring seasoned perspective to market complexities and critical strategic decisions.
Senior executive leadership built on 30 years in life sciences — supporting innovators across capital formation, product launches, and growth inflection points.
